Foghorn Therapeutics (FHTX) Morgan Stanley 22nd Annual Global Healthcare Conference summary

Platform and scientific approach

• Focuses on chromatin biology to regulate gene expression, targeting underexplored mechanisms in oncology.

• Developed a platform integrating deep biological understanding, specialized assays, and expertise in protein production.

• Utilizes a modality-agnostic approach, advancing both enzymatic inhibitors and protein degraders.

• Sees potential for applications beyond oncology, contingent on capital allocation.

• Ongoing challenges include achieving therapeutic selectivity and drugging difficult targets like transcription factors.

FHD-286 program updates

• FHD-286 is a dual SMARCA2/4 inhibitor, with initial studies in AML and uveal melanoma.

• Uveal melanoma study showed some activity but was not advanced due to tolerability and competitive landscape.

• AML study faced a clinical hold due to differentiation syndrome concerns, later resolved with FDA.

• Current focus is a combination study with cytarabine in relapsed/refractory AML, with a go/no-go decision expected in Q4.

• A 20%+ response rate and achievement of CRs are set as efficacy thresholds for further development.

Pipeline and indication expansion

• Indication expansion for FHD-286 depends on safety, tolerability, and capital allocation.

• Strategic partnerships are considered for broader development, especially in solid tumors.

• Additional programs include CBP and EP300 selective degraders, with CBP aiming for IND in 2025.

• Long-acting formulation technology enables biweekly dosing and improved coverage.